A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Trial Profile

A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2015

At a glance

  • Drugs XP 23829 (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors XenoPort
  • Most Recent Events

    • 16 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Sep 2015 Results published in XenoPort media release.
    • 15 Sep 2015 Primary endpoint (The percent change in PASI (Psoriasis Area and Severity Index) score from Baseline) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top